louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06118229: A Study to Explore the Role and Impact of Wearable Smart Devices in Perioperative NSCLC Patients
Official title: A Prospective Observational Study to the Role and Impact of Wearable Smart Devices in Perioperative NSCLC Patients
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Non Small Cell Lung Cancer
Keywords: Non Small Cell Lung Cancer
Wearable Devices
Lead sponsor: The First Affiliated Hospital of Guangzhou Medical University
Sponsor class: OTHER
First posted: 2023-11-07
Enrollment: 300
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Continuously enroll all patients with non-small cell lung cancer, histopathologically confirmed

Brief summary: The trial was designed as a single-center non-interventional prospective observational study to explore the role and impact of wearable smart devices in perioperative NSCLC patients.


Eligibility criteria: Inclusion Criteria:

1. Participants must provide voluntary consent to participate in this research and possess the capacity to sign an informed consent form.
2. Participants must be aged over 18 years.
3. Participants must have undergone pulmonary resection surgery with a postoperative pathological confirmation of primary lung cancer.

Exclusion Criteria:

1. Patient refusal to participate in this research.
2. Inability to wear wearable smart monitoring devices due to various reasons.
3. The pathological report suggests a non-small cell lung cancer (NSCLC) exclusion.
4. History of secondary lung cancer surgery.

Primary outcomes:
measure: Postoperative length of hospital stay
timeFrame: From time of surgery to time of discharge from the hospital (assessed up to 30 days)
Secondary outcomes:
measure: Operative time
timeFrame: From time of the start of surgery to the end of surgery
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: Department of Thoracic Surgery and Oncology, The First Affiliated Hospital of Guangzhou Medical University
state: Guangdong
Study officials:
affiliation: The First Affiliated Hospital of Guangzhou Medical University
name: Jianxing He, M.D
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05596929: Build-up Computed Assisted History Taking, Physical Examination and Diagnosis System of Emergency Patient Through Machine Learning (II)
Official title: Build-up Computed Assisted History Taking, Physical Examination and Diagnosis System of Emergency Patient Through Machine Learning (II)
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Internal Disease
Keywords: Artificial intelligence
Lead sponsor: National Taiwan University Hospital
Sponsor class: OTHER
First posted: 2022-10-27
Enrollment: 3000
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: In emergency department（ED）, physicians need to complete patient evaluation and management in a short time, which required different history taking, and physical examination skill in healthcare system.

Natural language processing（NLP） became easily accessible after the development of machine learning（ML）. Besides, electronic medical record（EMR） had been widely applied in healthcare systems. There are more and more tools try to capture certain information from the EMR help clinical workers handle increasing patient data and improving patient care.

However, to err is human. Physicians might omit some important signs or symptoms, or forget to write it down in the record especially in a busy emergency room. It will lead to an unfavorable outcome when there were medical legal issue or national health insurance review. The condition could be limited by a EMR supporting system. The quality of care will also improve.

The investigators are planning to analyze EMR of emergency room by NLP and machine learning. To establish the linkage between triage data, chief complaint, past history, present illness and physical examination. The investigators will try to predict the tentative diagnosis and patient disposition after the relationship being found. Thereafter, the investigators could try to predict the key element of history taking and physical examination of the patient and inform the physician when the miss happened. The investigators hope the system may improve the quality of medical recording and patient care.


Eligibility criteria: Inclusion Criteria:

* Over twenty years old
* Non-traumatic patient

Exclusion Criteria:

* Excluding the patients for administration reasons (issuing a medical certificate)
* Excluding the patients for non-emergency reasons like simply acupuncture, virus screening and prescription for medication.
* Excluding Patients who allocated to critical care station

Primary outcomes:
measure: Senior doctor appraisal
timeFrame: 24 hours
Secondary outcomes:
measure: Accuracy of diagnosis prediction
timeFrame: patient discharge from ED, up to 1 week
measure: Rationality of diagnosis prediction
timeFrame: 24 hours
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: National Taiwan University Hospital
Study officials:
affiliation: National Taiwan University Hospital
name: Huang, Dr.
role: STUDY_CHAIR
References:
Clinical trial NCT06660329: Efficacy and Safety of Tofacitinib in Refractory Blau Syndrome
Official title: Efficacy and Safety of Tofacitinib in Patients with Refractory Blau Syndrome: a Prospective Cohort Study
Study type: INTERVENTIONAL
Overall status: ENROLLING_BY_INVITATION
Phase: PHASE4
Conditions: Blau Syndrome
Keywords: Blau syndrome
Janus kinase inhibitors
Lead sponsor: Peking Union Medical College Hospital
Sponsor class: OTHER
First posted: 2024-10-28
Enrollment: 30
Sex: ALL
Minimum age (years): 0
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a prospective cohort study to observe the efficacy and safety of Tofacitinib in children with Blau syndrome (BS). The investigators would analyze the rate of remission or low disease activity after treatment as well as changes in inflammatory markers, patients' and physician's global assessment of disease activity to determine the efficacy and safety of Tofacitinib.


Eligibility criteria: Inclusion Criteria:

* Patients who have pathogenic mutation(s) in NOD2 gene;
* Patients who have clinical manifestations such as granulomatous dermatitis, arthritis, uveitis, vasculitis, interstitial lung disease and so on;
* Clinical remission was not achieved after ≥12 weeks of treatment with at least one immunosuppressant or biologics.

Exclusion Criteria:

Patients will not be included if meets any of the following criteria:

* Being treated with IL-1 inhibitor, or other biological agents;
* Pregnant and lactating women;
* Serious organ function failure, expected life time less than 6 months.

Primary outcomes:
measure: rate of remission or low disease activity
timeFrame: From enrollment to the end of treatment at 6 months
Secondary outcomes:
measure: RCB(Response in Chinese children with Blau syndrome) 30, 50, 70 response rates
timeFrame: From enrollment to the end of treatment at 3, 6, 9, 12 months
measure: Changes in inflammatory markers (including erythrocyte sedimentation rate, C reactive protein), cytokines (including IL-1β, IL-6, IL-17, IL-18, TNFα, IFN γ) and expression of type I interferon-stimulated genes over baseline
timeFrame: From enrollment to the end of treatment at 1,3, 6, 9, 12 months
measure: Proportion of recurrent uveitis
timeFrame: From enrollment to the end of treatment at 12 months
measure: Incidence of new organ involvement
timeFrame: From enrollment to the end of treatment at 1,3, 6, 9, 12 months
measure: Number of participants with adverse effect
timeFrame: From enrollment to the end of treatment at 12 months
Other outcomes:
Locations:
city: Beijing
country: China
facility: Peking Union Medical College Hospital
Study officials:
References:
Clinical trial NCT04970329: Corneal Thickness Changes in Patient Undergoing Dry Eye Managment
Official title: Corneal Thickness Changes in Patient Undergoing Dry Eye Managment
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Dry Eye Disease
Lead sponsor: University of Faisalabad
Sponsor class: OTHER
First posted: 2021-07-21
Enrollment: 96
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: 96 eyes will be divided into 3 groups (32 eyes each) and will be provided intervention which is Polyethylene Glycol 400 0.4%-Propylene Glycol 0.3%. , Dextran 0.1%Hypromellose 0.3%, and placebo(normal saline)
Primary purpose: TREATMENT

Brief summary: The purpose of this research is to the determine effect of dry eye and to compare the effect of artificial tears on central and peripheral corneal thickness.

Detailed description: In this randomized controlled trial, 96 eyes of females with dry eye will be recruited through random sampling. Dry eye assessments will be done including TBUT, Schirmer test 1, and OSDI questionnaire. 96 eyes will be divided into 3 groups (32 eyes each) and will be provided intervention which is Polyethylene Glycol 400 0.4%-Propylene Glycol 0.3%. , Dextran 0.1%Hypromellose 0.3%, and placebo(normal saline) through randomization by an unmasked investigator. Changes in central and peripheral corneal thickness will be evaluated by corneal topography. Patients will be evaluated at baseline, after 15 days, after 1 month, and re-evaluated after 1 month of cessation of treatment.

Eligibility criteria: Inclusion Criteria:

● Females with ages ranging between 18-40 years and OSDI scores greater than 13, ametropia of up to 1DS of SE with astigmatism of less than 0.5DC, and Emmetropes.

Exclusion Criteria:

* Refractive error of more than ±1 Ds of SE and astigmatism of greater than ±0.5DC.
* Corneal surface disease other than dry eye disease.
* Corneal ectasia.
* Corneal or eyelid infections
* Age \< 18 and \>40 years.
* History of contact lens wears within the past three months.
* Male will be excluded because sex has a large influence on the symptomatology of DED Males have significantly low symptom scores as compared to females.
* Corneal surgeries.
* History of ocular /systemic disease within the past 6 months.
* The patients already receiving any kind of treatment for DED and other ocular diseases.

Primary outcomes:
measure: Change in Corneal Thickness in microns
timeFrame: one month
measure: Change in Corneal Thickness in microns after treatment discontinuation.
timeFrame: one month
Secondary outcomes:
measure: Improvement in dry eye
timeFrame: one month
Other outcomes:
Locations:
city: Faisalabad
country: Pakistan
facility: The University of Faisalabad
state: Punjab
Study officials:
References:
Clinical trial NCT02357329: Food Composition and Palatability
Official title: Food Composition and Palatability
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Fat Taste
Keywords: fat taste
food preference
consumption
free fatty acids
Lead sponsor: Purdue University
Sponsor class: OTHER
First posted: 2015-02-06
Enrollment: 52
Sex: ALL
Minimum age (years): 18
Maximum age (years): 64
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: ECOLOGIC_OR_COMMUNITY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: unselected convenience sample

Brief summary: This study will investigate fat taste and if free fatty acids (FFA) in food function as a signal for fat content. FFA are quite unpleasant - the investigators want to measure if the concentration in different foods correlates with hedonic preference. FFA concentration from a variety of foods will be used to determine if people who have greater sensitivity for FFA find foods with higher FFA concentrations less acceptable. Further, this study with determine whether the relationship between fat taste and hedonic food preference is modified by sex and body mass index (BMI).


Eligibility criteria: Inclusion Criteria:

* Age 18-64
* Healthy
* Non-smoker

Exclusion Criteria:

* Food allergies
* Inability to detect and identify basic tastes

Primary outcomes:
measure: NEFA sensitivity (Participants will taste and rate 10 solutions based on intensity)
timeFrame: 1 day
Secondary outcomes:
measure: Food consumption and preference (Participants will answer questions regarding consumption of foods and preference)
timeFrame: 1 day
Other outcomes:
Locations:
city: W. Lafayette
country: United States
facility: Purdue Univeristy
state: Indiana
Study officials:
References:
Clinical trial NCT05941429: Comparison of Cariostatic Effect of Nano-Silver Fluoride Versus Silver Diamine Fluoride
Official title: Comparison of Cariostatic Effect of Nano-Silver Fluoride Versus Silver Diamine Fluoride in a Group of Preschool Children
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE1
Conditions: Dental Caries in Children
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2023-07-12
Enrollment: 78
Sex: ALL
Minimum age (years): 3
Maximum age (years): 5
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study will be conducted to test the cariostatic effect of Nano Silver Fluoride in a comparison to Silver Diamine Fluoride in a group of preschool children.

Detailed description: Silver Diamine Fluoride has offered a non-invasive and easily performed method to manage dental caries in very young children.Studies shows that SDF has been proven to arrest caries in cavitated lesions and to prevent caries in sound teeth as Fluoride is effective in enhancing the remineralization of dental hard tissue and silver ion acts as an antibacterial agent. However, It was found that silver causes staining to the dental tissues with a black discoloration, which can be considered to be a main drawback specifically, when it is used on anterior teeth. Nano-silver fluoride varnish preparation showed high efficacy in arresting caries progression in primary teeth without causing black discoloration to the tissues.Silver diamine fluoride (SDF) .

Benefits for patient:

1. Non-invasive treatment leading to reduce patient anxiety and stress.
2. No drilling and filling.
3. Protects against further caries progression.

Benefits for the practitioner:

1. Provide alternative treatment options.
2. Pain-free procedure that facilitates child management and saves time.

Benefits for the community:

1. Increasing overall oral health
2. Provides more information by testing new material
3. To provide better service quality.

Eligibility criteria: Inclusion Criteria:

* Children aged from 3 to 5 years
* clinical diagnosis of active dentinal caries in primary teeth
* Co-operative participants and free of any systemic diseases

Exclusion Criteria:

* Children whose parents refuse to sign consent
* Primary teeth with pulp involvement, pain, mobility, abscess, sinus, fistula; or discoloration related to tooth non-vitality.

Primary outcomes:
measure: caries lesion activity and severity assessment using Nyvad criteria
timeFrame: baseline
measure: caries lesion activity and severity assessment using Nyvad criteria
timeFrame: 3 weeks
measure: caries lesion activity and severity assessment using Nyvad criteria
timeFrame: 6 months
Secondary outcomes:
measure: ICDAS II
timeFrame: baseline
measure: ICDAS II
timeFrame: 3 weeks
measure: ICDAS II
timeFrame: 6 months
Other outcomes:
Locations:
city: Giza
country: Egypt
facility: Cairo university
Study officials:
References:
Clinical trial NCT05659329: Retrospective Simplex High Viscosity (HV) Bone Cement Study
Official title: A Retrospective Multicenter Study to Review the Use of Simplex High Viscosity Bone Cement in Primary Total Knee Arthroplasty
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Arthritis Knee
Aseptic Loosening
Keywords: Bone Cement
Knee Arthroplasty
Lead sponsor: Stryker Orthopaedics
Sponsor class: INDUSTRY
First posted: 2022-12-21
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: The study population will include all non-censored subjects who have received the Triathlon total knee system cemented with Simplex HV and are available for objective analysis.

Brief summary: This study is a retrospective multicenter study to review the use of Simplex High Viscosity Bone Cement in Primary Total Knee Arthroplasty

Detailed description: This study is a retrospective investigation of subjects who have received primary Triathlon Total Knee Arthroplasty inserted with Simplex High Viscosity (HV) Cement to evaluate the success rate defined as absence of revision for aseptic loosening of components at two years postoperative.

Eligibility criteria: Inclusion Criteria:

* The Patient is age 18 or over at time of study device implantation
* Patients who have undergone primary Triathlon Total Knee Arthroplasty in which Simplex HV/Simplex HV Gentamicin was indicated for fixation and used on label
* Patients who have been followed for at least 24 months postoperatively

Exclusion Criteria:

* Patients who have undergone revision surgery
* Patients who have undergone bilateral Knee Arthroplasty
* Patients contraindicated for either the devices implanted, or the cement used, according to medical history review and instructions for use
* Patient has a cementless tibial baseplate.
* Patient has an active or suspected latent infection in or about the affected knee joint
* Patient has muscle loss or neuromuscular impairment in the affected limb that would create an unjustifiable risk
* Patient is immunologically suppressed or receiving steroids in excess of normal physiological requirements (e.g. \> 30 days)
* Patient has a known hypersensitivity to any of the cements constituents or in patients with severe renal failure
* Patient is a prisoner

Primary outcomes:
measure: Success rate
timeFrame: 24 months
Secondary outcomes:
measure: Knee Society Score (KSS) Results
timeFrame: pre-op, 2 years, optional 5 years
measure: Oxford Knee Score (OKS) Results
timeFrame: pre-op, 2 years, optional 5 years
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00974129: A Study of CCCTC-binding Factor (CTCF) in Infantile Hemangiomas
Official title: Infantile Hemangioma Tumor Size and C/T Polymorphism Within CTCF Binding Site Six
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Hemangioma
Lead sponsor: Yale University
Sponsor class: OTHER
First posted: 2009-09-10
Enrollment: 0
Sex: ALL
Maximum age (years): 1
Standard ages: CHILD
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients to be recruited will include infants with hemangiomas on any part of their body.

Brief summary: The purpose of this study is to evaluate the genotype of CTCF, a proven transcription factor, in patients with infantile hemangiomas and to monitor tumor growth. The investigators aim to determine whether or not the CTCF genotype might serve as an early and reliable predictor of tumor growth.

Detailed description: This study seeks to examine a potential relationship between CTCF genotype and hemangioma size and growth rate. In addition to the initial visit, patients will return to our clinic for evaluation at two weeks, one month, two months, six months, and one year. At each visit, patients' hemangiomas will be measured and photographed. At one point over the course of evaluation, a blood sample will be taken from each patient for evaluation of C/T polymorphism at CTCF binding site six.

Eligibility criteria: Inclusion Criteria:

* Hemangioma must appear within one month prior to enrollment

Exclusion Criteria:

* Hemangioma appeared before one month prior to enrollment

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: New Haven
country: United States
facility: Yale Dermatology Associates
state: Connecticut
Study officials:
affiliation: Yale University
name: Deepak Narayan, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04901429: Truncal Vagotomy in Patients Undergoing Revisional Sleeve Gastrectomy to Gastric Bypass
Official title: Truncal Vagotomy in Patients Undergoing Revisional Sleeve Gastrectomy to Gastric Bypass
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: GERD
Lead sponsor: Baylor Research Institute
Sponsor class: OTHER
First posted: 2021-05-25
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to investigate the efficacy of performing a truncal vagotomy along with a sleeve to bypass revision surgery in reducing the severity and/or incidence of gastroesophageal reflux disease (GERD) post-surgery.


Eligibility criteria: Inclusion Criteria:

* Participating subjects will need to be \>18yrs of age and eligible for sleeve to bypass revision bariatric surgery.
* Undergoing sleeve to bypass revision bariatric surgery.

Exclusion Criteria:

* Patients who are under the age of 18.
* Not eligible for sleeve to bypass revision bariatric surgery.

Primary outcomes:
measure: GERD-HRQL scores
timeFrame: approximately 6 months post operation
measure: Esophageal pH monitoring
timeFrame: approximately 6 months post operation
measure: Reflux symptom index questionnaire
timeFrame: approximately 6 months post operation
Secondary outcomes:
Other outcomes:
Locations:
city: Dallas
country: United States
facility: Baylor University Medical Center
state: Texas
Study officials:
References: